James S. Talks

Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Journal: Eye (London, England)

Published: May 13, 2025

Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.

Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.

Journal: Ophthalmology science

Published: March 13, 2025

Development and standardisation of 'time-in-range' measurement for clinical endpoints in retinal diseases.

Development and standardisation of 'time-in-range' measurement for clinical endpoints in retinal diseases.

Journal: Eye (London, England)

Published: February 04, 2025

Deep Learning Algorithm for the Diagnosis and Prediction of Hydroxychloroquine Retinopathy: An International, Multi-institutional Study.

Deep Learning Algorithm for the Diagnosis and Prediction of Hydroxychloroquine Retinopathy: An International, Multi-institutional Study.

Journal: Ophthalmology. Retina

Published: January 14, 2025

Intervention design for artificial intelligence-enabled macular service implementation: a primary qualitative study.

Intervention design for artificial intelligence-enabled macular service implementation: a primary qualitative study.

Journal: Implementation science communications

Published: June 12, 2024

Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept.

Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: June 10, 2024

Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis.

Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis.

Journal: Current medical research and opinion

Published: May 30, 2024

2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort.

2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort.

Journal: Eye (London, England)

Published: May 10, 2024

Sickle Eye Project: a cross-sectional, non-interventional study of the prevalence of visual impairment due to sickle cell retinopathy and maculopathy in the UK.

Sickle Eye Project: a cross-sectional, non-interventional study of the prevalence of visual impairment due to sickle cell retinopathy and maculopathy in the UK.

Journal: BMJ open

Published: February 28, 2024

Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5.

Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5.

Journal: Eye (London, England)

Published: December 22, 2023

Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4.

Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4.

Journal: Eye (London, England)

Published: November 12, 2023

Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3.

Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3.

Journal: Eye (London, England)

Published: August 11, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026